含P_RP_L启动子的原核高效表达载体的组建及其应用

我们组建了一个含P_RP_L自动子的原核高效表达载体,它同时含有cI调控基因、多酶切点和两个强的转录终止序列。带起始密码子ATG的外源基因可以插入启动子下游的多酶切点,表达非融合蛋白,产品可供临床使用。我们实验室已用它成功地表达了人γ干扰素、人白细胞介素-2和人肿瘤坏死因子等,表达量均占菌体总蛋白的20％以上。     

经体外缺失诱变组建人杂交干扰素αA/γ

使用寡核苷酸指导的定点突变方法,将人αA型干扰素的完整基因与γ干扰素C端16个氨基酸的编码序列融合,在噬菌体λP_L启动子控制下,合成了一个杂交蛋白质。此蛋白质经抗人α干扰素单克隆抗体纯化后,在MDBK细胞上具有抗病毒活性,并像γ干扰素一样,可被依赖于cAMP的蛋白激酶磷酸化。[γ-~(32)P]杂交蛋白与MDBK细胞的结合,可被αA型干扰素大大抑制(70％)。     

人α降钙素基因相关肽与肿瘤坏死因子的融合表达

用半酶和半化学合成的方法合成和克隆了人ａ降钙素基因相关肽基因,将该基因融合在肿瘤坏死因子之后插入表达载体ｐＳＢ－９２中,使融合基因的５＇端直接置于大肠杆菌ＰＬ启动下游,采用３０℃培养,４２℃诱导,使ＴＮＦ与ＣＧＲＰ融合蛋白在大肠杆菌中获得了表达,表达的融合蛋白既有ＣＧＲＰ的结合活性（酶标检测为阳性）又有ＴＮＦ的生理功能（对Ｌ－９２９细胞的细胞毒活性）。表达菌裂解液走ＳＤＳ－聚丙烯酰胺凝胶电泳,显示     

人肿瘤坏死因子α抑制肽-抗炎酸性尾巴融合蛋白的原核表达及纯化

目的:表达和纯化人肿瘤坏死因子α抑制肽-抗炎酸性尾巴融合蛋白。方法:利用PCR搭接方法及基因合成方法获得目的基因,插入带有6×His标签的原核高效可溶性表达载体pET32a中,构建重组表达质粒pET32a-T9-ac-9,将重组表达质粒转化大肠杆菌BL21(DE3),经IPTG诱导目的基因表达;对融合蛋白进行Ni2+金属螯合柱纯化。结果:构建的重组表达质粒经PCR、内切酶鉴定及基因序列测定证实;目的蛋白在大肠杆菌中获得表达,SDS-PAGE显示相对分子质量为22.917×103;对表达产物进行了亲和层析纯化,从上清中获得了纯度较高的人肿瘤坏死因子α抑制肽-抗炎酸性尾巴融合蛋白。结论:获得了可溶性的人肿瘤坏死因子α抑制肽-抗炎酸性尾巴融合蛋白,为其生物学功能研究奠定了基础。     

重组人肿瘤坏死因子(TNF)和干扰素αA(IFNαA)融合蛋白的构建及表达

本文采用定位诱导缺失突变技术,经137个单核苷酸缺失,将串联的重组人肿瘤坏死因子(rhTNF)和重组干扰素αA(rhIFNaA)基因融合成编码单一蛋白的基因。融合基因在大肠杆菌表达后,活性检测证实,存在一旣具有TNF抗肿瘤、又具有IFN抗病毒双重活性的蛋白质。融合蛋白的活性较TNF和IFNαA分别低24倍和15倍。分子筛分析证实,融合蛋白分子量大于25kD。     

采用定位基因缺失突变技术在大肠杆菌中高效表达肿瘤坏死因子

肿瘤坏死因子α(TNF)为157个氨基酸组成的细胞因子,在克隆的全良cDNA的5’端有480bp的非编码区包括76个氨基酸信号肽编码区。本文采用寡核苷酸指导下的定位基因缺失突变方法,删除了这一非编码区及信号肽序列,并在成熟TNF分子第一个氨基酸密码前插入一个翻译起始密码(ATG),形成一个限制酶NcoI的识别位点ccATGG。然后取出含有成熟TNF全基因的Nc0I—Pst I片段,插入到原核表达载体pBv220中,获得了肿瘤坏死因子的高效表达菌株。活性检测结果表明,肿瘤坏死因子的表达量可达3．42×10。Μ／L菌液。sDs－PAGE电泳凝胶扫描结果显示,肿瘤坏死因子在大肠杆菌的表达量可占细菌可溶性总蛋白量的22．8％。抗呻瘤坏死因子单克隆抗体可以中和大肠杆菌表达的肿瘤坏死因子对L929细胞的细胞毒性。sD和ATG间插入31个核苷酸可使TNF表达量降低约10倍。     

人γ干扰素/β肿瘤坏死因子重组杂合蛋白对γ干扰素抗性细胞株的杀伤效应

已有大量研究资料表明,γ干扰素(Interferon γ,IFNγ)、淋巴毒素(Lymphotoxin,LT,又称TNFβ)或肿瘤坏死因子(TNFα),均有杀伤肿瘤细胞的细胞毒效应,并对其作用机理进行了广泛的研究。与此同时还对晚期肿瘤患者进行了临床治疗的探索,也取得了可喜的进展。但有些肿瘤细胞对这两种淋巴因子有天然的或逐渐获得的抗性现象,而且这两者在临床用有效抗癌剂量时,又可出现不同程度的副作用。为此有人用IFN和TNF联合处理肿瘤细胞,发现它们具有协同抗癌效应,这就为低剂量治疗肿瘤以减轻副作用提供了理论依据。据此,Feng等于1988年将人IFNγ和人TNFβ两个cDNA片段连接为融合基     

斑马鱼干扰素γ的克隆表达研究

目的：通过人工诱导斑马鱼干扰素的产生,证实两种斑马鱼干扰素γ基因ifng1-1和ifng1-2的存在,并克隆这两种干扰素基因,构建高效表达载体并做原核表达。方法：通过conA药浴,诱导斑马鱼干扰素γ的表达,即刻提取组织总RNA,并通过RT-PCR方法扩增两种干扰素γ基因。将目的基因连入表达载体pET24a,构建重组载体pET24a-ifng1-1和pET24a-ifng1-2。将载体转化BL21,并用IPTG诱导融合蛋白的表达。产物经SDS-PAGE检测,分析蛋白表达情况。结果：成功克隆了两种斑马鱼干扰素γ基因,构建了pET24a-ifng1-1和pET24a-ifng1-2重组载体,并实现了原核融合表达。结论：两种干扰素γ基因都能够被conA所诱生,且具有相似特性,表明两种干扰素γ都不是假基因,都有可能在免疫系统中发挥作用,本实验为进一步研究两种干扰素γ的功能奠定了基础。     

基因重组人肿瘤坏死因子-α突变体的构建

在详细分析ＴＮＦ α结构及有关ＴＮＦ α结构与功能关系研究的基础上,设计并人工合成了一对ＴＮＦ α结构基因点突变引物。应用ＰＣＲ和分子克隆技术构建了一种新型人肿瘤坏死因子（ＴＮＦ α）分子的编码基因,将该编码基因插入表达质粒,转化大肠杆菌,通过温度诱导获得了表达蛋白,对突变体克隆进行了ＤＮＡ电泳、酶切位点检测以及基因序列测定,并对突变体蛋白进行了ＳＤＳ ＰＡＧＥ电泳检测。     

突变型人IL-18的肿瘤靶向性改造及真核表达

为了构建肿瘤靶向性的人突变型IL-18新基因并进行真核表达,以重组PCR技术构建EGF-IL-18融合基因,利用 Bac-to-Bac杆状病毒表达系统和Sf 9昆虫细胞株（来自秋天草地夜蛾）表达融合基因,纯化表达产物,并以IFN-γ诱导实验和EGFR竞争结合实验初步评价融合蛋白的生物活性。测序证明构建的融合基因为原设计EGF-IL-18融合基因。SDS-PAGE和Western blot证明EGF-IL-18融合基因在昆虫细胞中获得表达,表达的融合蛋白的Mr约为20 000,与理论值相符,纯化后融合蛋白具有特异的IL-18单抗结合活性。IFN-γ诱导实验和EGFR竞争结合实验显示,该融合蛋白具有肿瘤导向性和抗肿瘤活性。表明对突变型IL-18成功地进行了肿瘤导向性改造并使其在真核细胞获得表达。     

重组人白细胞介素－6与肿瘤坏死因子突变体融合蛋白的构建及表达

针对肿瘤坏死因子（ＴＮＦ）在肿瘤治疗剂量下产生的严重毒副作用及一些肿瘤细胞上白细胞介素－６（ＩＬ－６）受体明显增高的事实,根据ＴＮＦ结构与功能研究的最新信息,利用ＰＣＲ技术,对人ＴＮＦα基因进行了改造,并将其与人ＩＬ－６成熟肽编码区ｃＤＮＡ通过人工接头进行融合。融合蛋白在大肠杆菌中表达后,Ｗｅｓｔｅｒｎｂｌｏｔ分析表明,分子量约为３７ｋＤ;活性检测结果证实,该融合蛋白兼具有ＴＮＦ抗肿瘤活性和结合ＩＬ－６受体的能力,在高表达ＩＬ－６受体的人骨髓瘤细胞上测得的细胞毒活性较同样位点突变的ＴＮＦ高约３倍。     

TRAF6-GST融合蛋白在大肠杆菌中的表达及纯化

目的:在大肠杆菌中表达肿瘤坏死因子受体相关因子6(TRAF6)与GST的融合蛋白并进行纯化。方法:采用PCR方法从肝文库中扩增编码TRAF6的DNA片段,将其插入原核表达载体pGEX-4T-2,构建GST-TRAF6原核表达载体,并转入大肠杆菌BL21(DE3)中,用IPTG诱导表达;用谷胱甘肽-琼脂糖珠亲和纯化表达的GST-TRAF6融合蛋白。结果:酶切鉴定和测序分析显示,长为1569 bp的TRAF6 DNA片段在pGEX-4T-2-TRAF6中的碱基序列、插入位点及读框正确,且位于表达载体的GST序列下游;经IPTG最佳浓度0.5 mmol/L诱导表达、亲和纯化后,获得了相对分子质量约85×103的GST-TRAF6融合蛋白。结论:构建了重组GST-TRAF6原核表达载体,获得了GST-TRAF6的大肠杆菌BL21表达菌株及GST-TRAF6融合蛋白,利于深入研究TRAF6的功能。     

Fusion protein of the hyaluronan binding domain from human TSG-6 with luciferase for assay of hyaluronan

The gene expression plasmid, pET-Lmluc, for the fusion protein of the hyaluronan binding domain from human TSG-6 [product of tumor necrosis factor (TNF)-stimulated gene-6] and luciferase from Renilla reniformis was constructed. The fused gene was expressed in Escherichia coli and the resulted insoluble Lm-luc fusion protein was purified and refolded to recover both the hyaluronan binding capability and the luciferase activity. Hyaluronan as low as 1 ng ml^–1 was detected by using the indirect enzymatic immunological assay with the refolded Lm-luc fusion protein.     

Stable Escherichia coli-Clostridium acetobutylicum shuttle vector for secretion of murine tumor necrosis factor alpha.

Recombinant plasmids were constructed to secrete mouse tumor necrosis factor alpha (mTNF-alpha) from Clostridium acetobutylicum. The shuttle plasmids contained the clostridial endo-beta1, 4-glucanase (eglA) promoter and signal sequence that was fused in frame to the mTNF-alpha cDNA. The construction was first tested in Escherichia coli and then introduced in C. acetobutylicum DSM792 by electroporation. Controls confirmed the presence and stability of the recombinant plasmids in this organism. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and an in vitro cytotoxic assay were used to monitor expression and secretion of mTNF-alpha during growth. Significant levels of biologically active mTNF-alpha were measured in both lysates and supernatants. The present report deals with investigations on the elaboration of a gene transfer system for cancer treatment using anaerobic bacteria.     

Isolation and characterization of eight tumor necrosis factor-induced gene sequences from human fibroblasts.

A lambda cDNA library was prepared from polyadenylated RNA isolated from quiescent human diploid FS-4 fibroblasts stimulated with tumor necrosis factor for 3 h. Differential screening was used to isolate cDNA sequences that are stimulated by tumor necrosis factor. Eight distinct tumor necrosis factor-stimulated gene sequences (designated TSG-1, -6, -8, -12, -14, -21, -27, and -37) were partially sequenced and compared with known sequences from GenBank. TSG-1 was identical to the gene for interleukin-8. TSG-8 corresponded to the gene for monocyte chemotactic and activating factor. TSG-21 and -27 were identical to the genes for collagenase and stromelysin, respectively. The other four sequences showed no homologies with known genes. Patterns of induction of mRNAs corresponding to the eight cloned cDNAs by various cytokines, growth factors, and activators of second messenger pathways were analyzed in FS-4 cells.     

Chemical-enzymatic synthesis and cloning of DNA, coding the signal for secretion of proteins in gram-negative bacteria

Chemical-enzymatic synthesis of an artificial gene encoding leader peptide and 22 N-terminal amino acids of mature carboxypeptidase G2 from Pseudomonas sp. followed by enterokinase signal sequence (Asp4Lys) has been accomplished. The resulted DNA was fused with semi-synthetic gene coding for polypeptide 4-157 of mature human tumour necrosis factor (TNF) and then placed under control of early promoters of T7 bacteriophage. The expression products of the construct obtained was analysed using anti-TNF anti-serum. In E.coli leader peptide was cleaved off during translocation through inner membrane and the resultant product was found in membrane fraction.     

The cytomegaloviral protein pUL138 acts as potentiator of tumor necrosis factor (TNF) receptor 1 surface density to enhance ULb'-encoded modulation of TNF-α signaling

Human cytomegalovirus is a ubiquitous herpesvirus that establishes lifelong latent infection. Changes in immune homeostasis induce the reactivation of lytic infection, which is mostly inapparent in healthy individuals but often causes overt disease in immunocompromised hosts. Based on discrepant tumor necrosis factor receptor 1 surface disposition between human cytomegalovirus AD169 variants differing in the ULb' region, we identified the latency-associated gene product pUL138, which also is expressed during productive infection, as a selective potentiator of tumor necrosis factor receptor 1, one of the key receptors of innate immunity. Ectopically expressed pUL138 coprecipitated with tumor necrosis factor receptor 1, extended the protein half-life, and enhanced its signaling responses, thus leading to tumor necrosis factor receptor 1 hyperresponsiveness. Conversely, the targeted deletion of UL138 from the human cytomegaloviral genome strongly reduced tumor necrosis factor receptor 1 surface densities of infected cells. Remarkably, the comparison of UL138 deficiency to ULb' deficiency revealed the presence of further positive modulators of tumor necrosis factor alpha signal transduction encoded within the human cytomegalovirus ULb' region, identifying this region as a hub for multilayered tumor necrosis factor alpha signaling regulation.